What is Aqtual?
Aqtual is at the forefront of precision medicine, developing advanced products for chronic disease management and oncology. The company's core innovation lies in its proprietary cell-free DNA (cfDNA)-based platform, which offers a novel approach to evaluating protein regulation, epigenetics, and transcriptomics. By analyzing cfDNA fragments in blood, Aqtual's technology enables efficient and robust real-time analysis of disease progression and treatment efficacy, overcoming the limitations of earlier cfDNA methodologies. This technological advantage positions Aqtual to make significant contributions to personalized healthcare.
How much funding has Aqtual raised?
Aqtual has raised a total of $47M across 2 funding rounds:
Series A
$16M
Series B
$31M
Series A (2023): $16M with participation from Genoa Ventures and Manta Ray Ventures
Series B (2025): $31M led by Yu Galaxy, Genoa Ventures, Manta Ray Ventures, and BOLD Capital Partners
Key Investors in Aqtual
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies at the intersection of biology and technology, aiming to empower category-defining companies that can transform industries and create a healthier world.
Manta Ray Ventures
Manta Ray Ventures is an early-stage venture capital fund that supports mission-driven founders tackling significant global challenges through advanced technologies, offering flexible capital and leveraging resources to assist portfolio companies.
Yu Galaxy
Yu Galaxy is a venture capital firm focused on partnering with entrepreneurs to develop impactful products, services, and technologies, investing across diverse sectors to create category-defining companies and lead early fundraising rounds.
What's next for Aqtual?
With the recent infusion of $31M in a major strategic investment, Aqtual is poised for accelerated growth and market expansion. This Series B financing, following a Series A round, signals the company's transition into a scaling phase. The capital will likely be deployed to further enhance its cfDNA platform, expand its product pipeline, and strengthen its commercialization efforts. Investor backing from firms like Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and BOLD Capital Partners suggests a strategic focus on advancing Aqtual's technology and solidifying its market position in the competitive precision medicine landscape. The company's trajectory indicates a strong potential for future breakthroughs in chronic disease and oncology treatment.
See full Aqtual company page
